Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 2
2003 1
2004 2
2006 1
2007 2
2008 2
2009 2
2010 1
2011 1
2013 1
2014 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
BMS-275183-induced gene expression patterns in head and neck carcinoma.
Yoo GH, Tran VR, Lemonnier LA, Ezzat WH, Subramanian G, Piechocki MP, Ensley JF, Lonardo F, Kim H, Lin HS. Yoo GH, et al. Am J Otolaryngol. 2007 Sep-Oct;28(5):309-15. doi: 10.1016/j.amjoto.2006.10.001. Am J Otolaryngol. 2007. PMID: 17826531
The purpose of this study is to identify the biological activity of BMS-275183 on HNSCC. MATERIALS AND METHODS: Head and neck squamous cell carcinoma cell lines, HN6, HN12, and HN30, were exposed to BMS-275183. BMS-275183-induced growth s …
The purpose of this study is to identify the biological activity of BMS-275183 on HNSCC. MATERIALS AND METHODS: Head and neck …
Preclinical pharmacology of BMS-275183, an orally active taxane.
Rose WC, Long BH, Fairchild CR, Lee FY, Kadow JF. Rose WC, et al. Clin Cancer Res. 2001 Jul;7(7):2016-21. Clin Cancer Res. 2001. PMID: 11448919
BMS-275183 is a taxane, the mechanism of action of which is like other known taxanes, and is the polymerization of tubulin. BMS-275183 given p.o. was as effective as i.v. paclitaxel in five tumor models [murine M109 lung and C3H mammary 16/C, and human …
BMS-275183 is a taxane, the mechanism of action of which is like other known taxanes, and is the polymerization of tubulin. …
A phase 1 study of BMS-275183, a novel oral analogue of paclitaxel given on a daily schedule to patients with advanced malignancies.
Heath EI, Lorusso P, Ramalingam SS, Awada A, Egorin MJ, Besse-Hamer T, Cardoso F, Valdivieso M, Has T, Alland L, Zhou X, Belani CP. Heath EI, et al. Invest New Drugs. 2011 Dec;29(6):1426-31. doi: 10.1007/s10637-010-9498-z. Epub 2010 Aug 3. Invest New Drugs. 2011. PMID: 20680660 Clinical Trial.
The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase II dose of BMS-275183 when given on a continuous daily schedule to patients with advanced solid tumor(s). ...CONCLUSIONS: BM …
The present study was designed to: (i) assess the safety and tolerability of BMS-275183, and (ii) determine a suitable Phase I …
Effect of food on the pharmacokinetic behavior of the potent oral taxane BMS-275183.
Bröker LE, Valdivieso M, Pilat MJ, Deluca P, Zhou X, Parker S, Giaccone G, Lorusso PM. Bröker LE, et al. Clin Cancer Res. 2008 Jul 1;14(13):4186-91. doi: 10.1158/1078-0432.CCR-07-4594. Clin Cancer Res. 2008. PMID: 18593998 Free article. Clinical Trial.
PURPOSE: BMS-275183 is a potent oral paclitaxel analogue that previously showed promising activity. ...CONCLUSIONS: Food intake does not affect the pharmacologic exposure to BMS-275183. BMS-275183 can be given orally by flat dosing instea …
PURPOSE: BMS-275183 is a potent oral paclitaxel analogue that previously showed promising activity. ...CONCLUSIONS: Food intak …
Metabolism and excretion of an oral taxane analog, [14C]3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxy-paclitaxel (BMS-275183), in rats and dogs.
Ly VT, Caceres-Cortes J, Zhang D, Humphreys WG, Ekhato IV, Everett D, Cömezoğlu SN. Ly VT, et al. Drug Metab Dispos. 2009 May;37(5):1115-28. doi: 10.1124/dmd.108.025809. Epub 2009 Feb 5. Drug Metab Dispos. 2009. PMID: 19196843
In this study, the metabolism and excretion of [(14)C]BMS-275183 were evaluated after a single oral administration of [(14)C]BMS-275183 to rats and dogs (15 and 1 mg/kg, respectively). ...Fecal excretion was the major route of elimination for [(14)C] …
In this study, the metabolism and excretion of [(14)C]BMS-275183 were evaluated after a single oral administration of [(14)C] …
Phase I trial with BMS-275183, a novel oral taxane with promising antitumor activity.
Bröker LE, de Vos FY, van Groeningen CJ, Kuenen BC, Gall HE, Woo MH, Voi M, Gietema JA, de Vries EG, Giaccone G. Bröker LE, et al. Clin Cancer Res. 2006 Mar 15;12(6):1760-7. doi: 10.1158/1078-0432.CCR-05-2093. Clin Cancer Res. 2006. PMID: 16551860 Free article. Clinical Trial.
PURPOSE: BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. ...EXPERIMENTAL DESIGN: A cycle consisted of four weekly doses of BMS-275183. The starting dose was 5 mg, which was increased by 100% increments (i.e., 5, 10, 20 …
PURPOSE: BMS-275183 is an orally administered C-4 methyl carbonate analogue of paclitaxel. ...EXPERIMENTAL DESIGN: A cycle con …
The discovery of BMS-275183: an orally efficacious novel taxane.
Mastalerz H, Cook D, Fairchild CR, Hansel S, Johnson W, Kadow JF, Long BH, Rose WC, Tarrant J, Wu MJ, Xue MQ, Zhang G, Zoeckler M, Vyas DM. Mastalerz H, et al. Bioorg Med Chem. 2003 Oct 1;11(20):4315-23. doi: 10.1016/s0968-0896(03)00495-4. Bioorg Med Chem. 2003. PMID: 13129567
CYP3A4-mediated ester cleavage as the major metabolic pathway of the oral taxane 3'-tert-butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183).
Zhang D, Ly VT, Lago M, Tian Y, Gan J, Humphreys WG, Cömezoglu SN. Zhang D, et al. Drug Metab Dispos. 2009 Apr;37(4):710-8. doi: 10.1124/dmd.108.024398. Epub 2009 Jan 21. Drug Metab Dispos. 2009. PMID: 19158314
3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183) is an orally available taxane analog that has the potential to be used as an oral agent to treat cancers. ...Unlike the other taxanes, the hydr …
3'-tert-Butyl-3'-N-tert-butyloxycarbonyl-4-deacetyl-3'-dephenyl-3'-N-debenzoyl-4-O-methoxycarbonyl-paclitaxel (BMS-275183) is …
A phase I safety and pharmacologic study of a twice weekly dosing regimen of the oral taxane BMS-275183.
Bröker LE, Veltkamp SA, Heath EI, Kuenen BC, Gall H, Astier L, Parker S, Kayitalire L, Lorusso PM, Schellens JH, Giaccone G. Bröker LE, et al. Clin Cancer Res. 2007 Jul 1;13(13):3906-12. doi: 10.1158/1078-0432.CCR-06-2875. Clin Cancer Res. 2007. PMID: 17606724 Clinical Trial.
PURPOSE: BMS-275183, an orally administered C-4 methyl carbonate paclitaxel analogue, showed promising activity in a phase I trial investigating a weekly treatment regimen, but was associated with a relatively high incidence of neuropathic side effects. The current …
PURPOSE: BMS-275183, an orally administered C-4 methyl carbonate paclitaxel analogue, showed promising activity in a phase I t …
Therapeutic synergy of oral taxane BMS-275183 and cetuximab versus human tumor xenografts.
Rose WC, Wild R. Rose WC, et al. Clin Cancer Res. 2004 Nov 1;10(21):7413-7. doi: 10.1158/1078-0432.CCR-04-1045. Clin Cancer Res. 2004. PMID: 15534118
PURPOSE: Combination therapy consisting of an oral taxane, BMS-275183, and the anti-epidermal growth factor receptor monoclonal antibody, cetuximab, was assessed for enhanced therapeutic benefit in preclinical tumor models. ...Similar efficacy benefits were obtained …
PURPOSE: Combination therapy consisting of an oral taxane, BMS-275183, and the anti-epidermal growth factor receptor monoclona …
16 results